We use cookies for a better user experience. Read our Privacy Policy

I Agree

Viral Conjunctivitis Pipeline Drugs Market

Viral Conjunctivitis Pipeline Drugs Market (Drug Type - FST-100 and APD-209) - Global Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023

Viral Conjunctivitis Pipeline Drugs Market is Driven by Highly Contagious Nature of the Infection

The global viral conjunctivitis pipeline drugs market is likely to observe substantial development over the years of projection due to increased awareness about the infection across the globe. Viral conjunctivitis is also known by the name of “pinkeye”. This infection is an extremely acute conjunctival infection that is generally caused by adenovirus. A few of the other viruses that is capable of causing conjunctival infection are poxvirus (vaccinia, molluscumcontagiosum), picornavirus (Coxsackie A24, enterovirus 70), herpes simplex virus (HSV), and varicella-zoster virus (VZV).

Patients infected with viral conjunctivitis need to avoid sharing pillowcases, napkins, towels, and touching their eyes. In addition to that, one may contact the infection via accidental inoculation of viral particles from the contaminated water of swimming pools and hands of the patient. Another person could also be infected through the droplets of infected tracks of upper respiratory system. Such high degree of contagiousness is likely to drive the global viral conjunctivitis pipeline drugs market over the years of projection.

Better Availability of Diagnostic Tests likely to Fuel Market Growth

In addition, augmented awareness about the infection together with better accessibility of diagnostic tests, increased healthcare-related expenditure, and an escalation of research and development activities are likely to boost the global viral conjunctivitis pipeline drugs market in the near future.

Symptoms of viral conjunctivitis comprise the following

  • intense redness of the eye
  • mild pain or burning sensation or discomfort in the eyes
  • mostly watery discharge from the eye
  • small amount of mucus form the eye, at times
  • Swollen and redness in the eyelids
  • Crustiness around the eyelids upon waking in the morning

On the flip side, global viral conjunctivitis pipeline drugs market is likely to be hampered by inadequate awareness pertaining to the advanced medical technologies, high cost. In addition, conjunctivitis is the result of infection caused by adenoviruses and enteroviruses, which are self-limiting in most of the conditions. The infection could be resolved in around seven to ten days.

Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.

The increasing investments from ophthalmic drug manufacturers for the development of efficient treatment for viral conjunctivitis, coupled with the increasing awareness among people and augmenting expenditure on healthcare, are accelerating the growth rate of this market significantly.

On the other hand, lower diagnosis rate of viral conjunctivitis is decreasing the patient pool for the treatment, causing major hindrance in the market’s growth.

Pipeline Drugs in U.S. Gain Momentum from Promising Results of Ongoing Clinical Trials

The U.K., the U.S., Germany, Australia, Japan, and Brazil are the key regional markets for viral conjunctivitis pipeline drugs. Considering the ongoing clinical trials, the U.S. is likely to occupy the leading position among these in the coming years. The major factors driving the growth in this market are promising results of the ongoing clinical trials, the increasing awareness regarding eye care among patients and medical professionals, the high cost of the drugs, and the availability of viral conjunctivitis diagnostic tests.

The U.S. market for viral conjunctivitis pipeline drugs is projected to report a CAGR of 46.50% during the period from 2020 to 2023.

APD-209 to Exceed FST-100 by 2023

APD-209 and FST-100 are the main viral conjunctivitis drugs in the pipeline. Among the two, FST-100 is projected to hold the largest share in the market by 2020. Foresight Biotherapeutics Inc. initiated the development of FST-100; however, the company was acquired by Shire Plc. in the midway. In May 2014, the drug completed its phase II clinical trial successfully and is expected to enter the phase III of clinical trials in 2016.

Presently, the APD-209 is witnessing moderate rise; however, in the coming years, it will report a higher demand than FST-100. The drug, being developed by Adenovir Pharma AB, is in its second phase of clinical trial. It is likely to enter the third phase by mid-2016.

The market for FST-100 is projected to rise at a CAGR of 27.40% between 2020 and 2023 while the APD-209 market is likely to report a CAGR of 55.0% during the same period.

Leading Players Focus on Research Activities Thanks to Escalating Demand for Targeted Drugs for Viral Conjunctivitis

On the forefront of the global viral conjunctivitis pipeline drugs market are Panoptes Pharma GES.M.B.H., Shire Plc., Allergan Plc, Novartis AG, NovaBay Pharmaceuticals Inc., Adenovir Pharma AB, NicOx S.A., and NanoViricides Inc. As the demand for targeted drugs for viral conjunctivitis is rising, leading enterprises are focusing aggressively on research activities for the development of efficient treatments as well as diagnostic tests for viral conjunctivitis. New entrants in this market are recommended to enhance their distribution networks through strategic partnerships and alliances with local distributors.

Viral Conjunctivitis Pipeline Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Table of Content

1. Preface
    1.1. Report Description
    1.2. Research Methodology
    1.3. Assumptions 
    1.4. Market Segmentation

2. Executive Summary
    2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
    2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market – Industry Analysis
    3.1. Introduction
           3.1.1. Sign and Symptoms 
           3.1.2. Diagnosis 
           3.1.3. Management 
    3.2. Market Dynamics
           3.2.1. Market Drivers
                   3.2.1.1. Large Unmet Needs 
                   3.2.1.2. Strong Pipeline 
           3.2.2. Restraints
                   3.2.2.1. Low diagnosis rate
                   3.2.2.2. Self-Limiting Condition 
           3.2.3. Opportunity
                   3.2.3.1. Investment in Rigorous R&D Activities
                   3.2.3.2. Strengthen Commercialization Activities
    3.3. Epidemiology 
    3.4. Patent Analysis of Pipeline Drugs 

4.  Market Segmentation – By Pipeline Drug 
    4.1. Introduction
    4.2. Market Revenue of FST-100 (SHP-640), 2020–2023, (US$ Mn)
    4.3. Market Revenue of APD-209, 2021–2023, (US$ Mn)
    4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation – By Country 
    5.1. Introduction
    5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn) 
    5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn) 
    5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn) 
    5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn) 
    5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn) 
    5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn) 

6. Recommendations

7. Company Profiles
    7.1. Adenovir Pharma AB
    7.2. Allergan plc
    7.3. NanoViricides, Inc.
    7.4. Shire plc
    7.5. NovaBay Pharmaceuticals, Inc.
    7.6. Novartis AG
    7.7. Panoptes Pharma GES.M.B.H.
    7.8. NicOx S.A. 

List of Tables

TABLE 1 Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
TABLE 2 Viral Conjunctivitis: Management 
TABLE 3 Epidemiology
TABLE 4 Patent Analysis of Pipeline Drugs
TABLE 5 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023
TABLE 6 Early Stage Preclinical Trials
TABLE 7 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020–2023

List of Figures

FIG. 1 Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
FIG. 2 Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
FIG. 3 Viral Conjunctivitis: Signs and Symptoms
FIG. 4 Market Revenue of FST-100, (US$ Mn), 2020–2023
FIG. 5 Market Revenue of APD-209, (US$ Mn), 2021–2023
FIG. 6 U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020–2023
FIG. 7 U.K. Market Revenue, (US$ Mn), 2021–2023
FIG. 8 Germany Market Revenue, (US$ Mn), 2021–2023
FIG. 9 Australia Market Revenue, (US$ Mn), 2022–2023
FIG. 10 Japan Market Revenue, (US$ Mn), 2022–2023
FIG. 11 Brazil Market Revenue, (US$ Mn), 2020–2023
FIG. 12 Allergan Financial Overview: (US$ Mn), 2012–2014
FIG. 13 NanoViricides, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 14 Shire plc, Financial Overview: (US$ Mn), 2013–2015
FIG. 15 NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 16 Novartis AG, Financial Overview: (US$ Mn), 2013–2015
FIG. 17 NicOx S.A., Financial Overview: (US$ Mn), 2013–2015 

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

923

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved